Background Safety of rechallenge of immune checkpoint inhibitor (ICI) after grade≥ 2
immune-related adverse events (irAEs) leading to ICI discontinuation remains unclear …

Importance Limited information is available on the safety of a rechallenge with an immune
checkpoint inhibitor (ICI) after an immune-related adverse event (irAE). Objective To identify …

Introduction Little evidence exists on the safety and efficacy of the rechallenge of immune
checkpoint inhibitors (ICIs) after immune-related adverse events (irAEs) in patients with …

Importance Although immune checkpoint inhibitors (ICIs), such as anti–PD-1 (programmed
cell death 1) or anti–PD-L1 (programmed cell death 1 ligand 1), have proved effective in …

Simple Summary This study examined the real-world experience and occurrence of immune-
related adverse events (irAEs) under cancer checkpoint immunotherapy, and the …

Background Data on spectrum and grade of immune-related adverse events (irAEs) in long-
term responders to immune checkpoint inhibitors (ICIs) are lacking. Methods We performed …

Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionised cancer
therapy but frequently cause immune-related adverse events (irAEs). Description of late …

Patients with cancer who developed severe, grade 3 or 4 immune-related adverse events
(irAEs) during therapy with immune checkpoint inhibitors are at risk for developing severe …

Background Immune-related adverse events (irAEs) remain generally unpredictable, and
severe irAEs remain challenging to detect early and manage. Very severe (grade IV–V) …

Aim The growing use of immune checkpoint inhibitors (ICIs) is associated with the
occurrence of immune-related adverse events (irAEs). Few data are published on systemic …